- Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway.
- Yanaihara N, Yoshino Y, Noguchi D, Tabata J, Takenaka M, Iida Y, Saito M, Yanagida S, Iwamoto M, Kiyokawa T, Chiba N, Okamoto A.
- Gynecol Oncol. 2022 Nov 17;168:83-91. doi: 10.1016/j.ygyno.2022.11.006. Epub ahead of print.
- PMID: 36403366
- PubMed abstract